RxDoctor Payments Data

Sherry Megalla, MD

Cardiovascular Disease · Bronx, NYNPI 1912162793

Payments from drug & device makers

$1,603in general payments, 2019–2025

Across 76 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$442
  • Boehringer Ingelheim$291
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
  • Kestra Medical Technology Services, Inc.$103
  • Pfizer$89
  • Novo Nordisk$87
  • plus $392 from 10 others

What the payments were for

  • Food & beverage$1,603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,603 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$259,227
Medicare patients
4,357
Services billed
8,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban165$211,447
XareltoRivaroxaban99$139,508
EntrestoSacubitril/Valsartan64$90,211
Repatha SureclickEvolocumab47$52,393
BrilintaTicagrelor20$21,739
JardianceEmpagliflozin12$18,187
FarxigaDapagliflozin Propanediol11$13,433
Metoprolol Succinate322$5,753
Atorvastatin Calcium256$2,654
Rosuvastatin Calcium187$2,126
Losartan Potassium154$1,481
Amlodipine Besylate214$1,412
Candesartan Cilexetil12$946
ClopidogrelClopidogrel Bisulfate80$854
Ezetimibe40$829

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$89$211,447165 claims
Johnson & JohnsonXarelto$48$139,50899 claims
NovartisEntresto$442$90,21164 claims
AstraZenecaBrilinta, Farxiga$26$35,17131 claims
Boehringer IngelheimJardiance$291$18,18712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →